Key result
Multidisciplinary management and delayed administration of dantrolene successfully rescued a 13-year-old adolescent with malignant hyperthermia and a peak temperature of 44.2°C.
Why the study?
Malignant hyperthermia is potentially fatal without early recognition and prompt aggressive treatment, especially when ready-made dantrolene is not immediately available.
Case Report (n=1)
No
Highlights the successful rescue of a severe case of malignant hyperthermia with a peak temperature of 44.2°C using delayed dantrolene and multidisciplinary management.
Answers are grounded in this paper and cite their sources.
Delayed dantrolene with multidisciplinary care may succeed in extreme malignant hyperthermia; single case leaves open prospective validation.
Malignant hyperthermia (MH) is an inherited skeletal muscle disorder caused primarily by a genetic mutation, usually in the calcium channel gene of the muscle. This mutation can lead to muscle hypersensitivity to volatile anesthetics (such as sevoflurane) and the depolarizing muscle relaxant succinylcholine, resulting in hyperthermia, muscle stiffness, metabolic disturbances, and other severe physiological reactions. This condition may prove fatal unless it is recognized in its early stages and treatment is administered promptly and aggressively. We report a 13-year-old adolescent who underwent laparoscopic appendectomy and developed MH after the use of inhalational anesthetics, manifested by unremitting hyperthermia with a maximum temperature of 44.2°C, muscle rigidity, tachycardia, hypercapnia; and malignant arrhythmias, cardiogenic shock, hyperkalemia, metabolic, and respiratory acidosis. After early and timely recognition, multidisciplinary management and administration of dantrolene, the case was successfully treated. Exome sequencing revealed a point mutation (amino acid change) on the RYR1 gene: c.12700G>C(p.Val4234Leu). Due to the lack of ready-made dantrolene in our hospital, the patient in this case received dantrolene treatment only 6 h after the first observation of high body temperature. We review the development of the disease and summarize the success of treatment and what can be done to improve the chances of saving the patient's life if dantrolene is not available in time.
No takes yet. Share an insight, caveat, or question.
Lan et al. (2023) conducted a case report in Malignant hyperthermia (n=1). Dantrolene and multidisciplinary management was evaluated on Successful rescue/treatment. Multidisciplinary management and delayed administration of dantrolene successfully rescued a 13-year-old adolescent with malignant hyperthermia and a peak temperature of 44.2°C.
Synapse has enriched 10 related papers. Consider them for comparative context: